EDIT News and Press, Editas Medicine Inc. From 01/25/24

2024-01-25 08:00:00 ET Summary Alex Carchidi calls the biotech sector highly risky and speculative, and says diversification is key for investors. Funding is currently difficult to obtain in the biotech industry, but a turnaround is expected. Competitive stories in gene editin...

2024-01-21 09:37:00 ET Editas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few similarities despite being at different stages of the biotech lifecycle. Both companies are betting that their acumen with gene editing will enable them to make...

2024-01-18 07:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-15 05:19:00 ET It's been a few years since the average investor behaved as if no challenge was too tough for America's biopharmaceutical industry. In turn, shares of gene-editing startup Editas Medicine (NASDAQ: EDIT) have collapsed by about 88% over the past three years des...

2024-01-10 00:43:09 ET Editas Medicine, Inc. (EDIT) J.P. Morgan 42nd Annual Healthcare Conference January 09, 2024 07:30 PM ET Company Participants Gilmore O'Neill - CEO Baisong Mei - CMO Erick Lucera - CFO Conference Call Participants Brian Cheng - J...

Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish in vivo preclinical proof-of-concept for an undisclosed indication , and continue to sublicense foundational IP St...

2024-01-08 07:45:00 ET Investing in cutting-edge companies is a bit riskier than investing in tried-and-tested players, but breaking new ground can sometimes offer outsized rewards. On that note, Editas Medicine (NASDAQ: EDIT) and Intellia Therapeutics (NASDAQ: NTLA) are bot...

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 42nd Annual J.P. Morgan Healthcare Conference o...

2023-12-29 19:03:08 ET More on CRISPR Therapeutics Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics Crispr Therapeutics: The Party Is Over (Rating Downgrade) Cell and gen...

2023-12-28 13:10:55 ET Summary Editas Medicine is transitioning from platform development to establishing itself as a key player in the commercial therapeutics market. The company's strategic priorities include fast-tracking the clinical development of EDIT-301, shifting focus to ...